NCT06430788View on ClinicalTrials.gov

A Study of Emapalumab for Pediatric Aplastic Anemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

May 21, 2029

Study Completion Date

May 21, 2029

Conditions
Aplastic AnemiaCytopeniaHypocellular Marrow
Interventions
BIOLOGICAL

Emapalumab

Emapalumab is an interferon gamma (IFNγ) blocking antibody

Trial Locations (6)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

19104

RECRUITING

Children's Hospital of Philadelphia (Data Collection AND Specimen Analysis), Philadelphia

23219

RECRUITING

Virginia Commonwealth University (Data Collection Only ), Richmond

45229

RECRUITING

Cincinnati Children's Hospital Medical Center (Data collection only), Cincinnati

53226

RECRUITING

Children's Hospital of Wisconsin (Data Collection Only), Milwaukee

NOT_YET_RECRUITING

Medical College of Wisconsin (Data Collection AND Data Analysis), Milwaukee

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER